# Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer

> **NCT00044291** · PHASE3 · COMPLETED · sponsor: **Intarcia Therapeutics** · enrollment: 865 (actual)

## Conditions studied

- Breast Neoplasms
- Neoplasms, Hormone-dependent

## Interventions

- **DRUG:** atamestane
- **DRUG:** toremifene
- **DRUG:** letrozole
- **DRUG:** aromatase inhibition
- **PROCEDURE:** hormone therapy
- **PROCEDURE:** endocrine therapy
- **PROCEDURE:** antiestrogen therapy

## Key facts

- **NCT ID:** NCT00044291
- **Lead sponsor:** Intarcia Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-06
- **Primary completion:** 2006-01
- **Final completion:** 2006-01
- **Target enrollment:** 865 (ACTUAL)
- **Last updated:** 2015-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00044291

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00044291, "Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00044291. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*